

UCSF Helen Diller Family
Comprehensive
Cancer Center

Adult Cancers

Breast (32 trials)
Cutaneous (14 trials)
Gastrointestinal (19 trials)
Genitourinary (24 trials)
Gynecological (6 trials)
Head and Neck (12 trials)
Malignant Hematology (30 trials)
Multiple / Ill-Defined Disease Sites (13 trials)
Neurologic Oncology (6 trials)
Thoracic (9 trials)
Other Trials (105 trials)
Total Trials = 270

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Prevention					
16752	NCT02620852	Esserman, Laura	The WISDOM Study (Women Informed to Screen Depending on Measures of Risk)	Screening	1-877-827-3222
227518	NCT04821141	Esserman, Laura	Randomized IIB Study of the Effect of Bazedoxifene plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer	Prevention	molly.baxter@ucsf.edu; rachel.woody@ucsf.edu
Breast > Breast Cancer Treatment					
ALLIANCE-A191901	NCT04379570	Cheng, Judy	Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions	Health Services Research	evelin.trejo@ucsf.edu
ALLIANCE-A012103	NCT05812807	Dixit, Niharika	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy	Treatment	1-877-827-3222
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
NRG-BR007	NCT04852887	Yoshida, Emi	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence score less than or equal to 18 Breast Cancer	Treatment	Bogdan.Eftimie@ucsf.edu
Breast > Symptom Management / Survivorship					
238010	NCT06215469	Rugo, Hope	Amma Portable Scalp Cooling System (PSCS) Study: A Post-market Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Early-stage Breast Cancer (Cooler Heads)	Supportive Care	1-877-827-3222
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
228014	NCT06055803	Beatty, Alexis	The Heart Health After Cancer Treatment (HEART-ACT): A pilot study of a multi-disciplinary health behavior intervention in people with a history of breast cancer to reduce heart disease risk after cancer treatment	Supportive Care	ivan.leung@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Early Stage Breast Cancer					
19753	NCT03562637	Melisko, Michelle	The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
237519	NCT05232916	Rugo, Hope	A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Surgery					
217510	NCT05020574	Piper, Merisa	Microbiome and Association with Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-Mastectomy with Implant-Based Breast Reconstruction	Supportive Care	laura.barnes@ucsf.edu
Breast > Breast Cancer Treatment > Radiation					
117515	NCT01570998	Alvarado, Michael	Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy following Breast-Conserving Surgery	Treatment	Amy.Deluca@ucsf.edu; Stig.Kreps@ucsfmedctr.org

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+					
227514	NCT05514054	Rugo, Hope	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	Treatment	Amy.Deluca@ucsf.edu
23752	NCT05573555	Chien, Jo	TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)	Treatment	Amy.Deluca@ucsf.edu
23756	NCT05508906	Chien, Jo	A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR inhibitor Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
227520	NCT05563220	Rugo, Hope	A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)	Treatment	Amy.Deluca@ucsf.edu
21758	NCT04862663	Rugo, Hope	A Phase Ib/III, Open-Label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Treatment	Amy.Deluca@ucsf.edu
207513	NCT03990896	Rugo, Hope	Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial	Treatment	Amy.Deluca@ucsf.edu
21753	NCT04802759	Rugo, Hope	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)	Treatment	Amy.Deluca@ucsf.edu
237535	NCT06105632	Melisko, Michelle	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY (C4391022)	Treatment	Amy.Deluca@ucsf.edu
23751	NCT05548127	Chien, Jo	TACTIVE-U: An interventional safety and efficacy Phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of vepdegestrant (ARV-471/PF-07850327), an oral Proteolysis Targeting Chimera, in combination with other anticancer treatments in participants Aged 18 years and Over with ER+ advanced or Metastatic breast cancer, Sub-study A (ARV-471 in combination with Abemaciclib)	Treatment	Amy.Deluca@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+					
237533	NCT06157892	Chien, Jo	A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors	Treatment	Amy.Deluca@ucsf.edu
24752	NCT06188559	Rugo, Hope	An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer	Treatment	Amy.Deluca@ucsf.edu
22756	NCT04829604	Rugo, Hope	A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd	Treatment	Amy.Deluca@ucsf.edu
ALLIANCE-A011801	NCT04457596	Rugo, Hope	THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Triple Negative					
187519	NCT03971409	Rugo, Hope	Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A multicenter, multi-arm Translational Breast Cancer Research Consortium study (TBCRC 047: InCITe) MASTER PROTOCOL	Treatment	Amy.Deluca@ucsf.edu
207513	NCT03990896	Rugo, Hope	Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial	Treatment	Amy.Deluca@ucsf.edu
23754	NCT05633654	Rugo, Hope	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy	Treatment	Amy.Deluca@ucsf.edu
237512	NCT05852691	Rugo, Hope	A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NAB-PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1 POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Phase I					
21758	NCT04862663	Rugo, Hope	A Phase Ib/III, Open-Label, Randomised Study of Capiwasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant					
097517	NCT01042379	Chien, Jo	I-SPY 2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2	Treatment	Amy.Deluca@ucsf.edu; adi.goldman@ucsf.edu; xenia.wong@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > In Situ > Neoadjuvant					
237522	NCT06075953	Esserman, Laura	DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study	Treatment	cristian.maldonadorodas@ucsf.edu; hannah.chay@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Adjuvant					
217519	NCT04893109	Rugo, Hope	A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)	Treatment	Amy.Deluca@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Cutaneous > Melanoma					
20863	NCT04598009	Tsai, Katy	A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma	Treatment	sonia.contrerasmartinez@ucsf.edu
23858	NCT05907304	Daud, Adil	An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations	Treatment	sonia.contrerasmartinez@ucsf.edu
22853	NCT05086692	Daud, Adil	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
228510	NCT05571839	Daud, Adil	A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
23851	NCT05608291	Daud, Adil	A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA	Treatment	sonia.contrerasmartinez@ucsf.edu
24853	NCT06346067	Daud, Adil	A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN'S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]	Treatment	sonia.contrerasmartinez@ucsf.edu
23857	NCT05987332	Tsai, Katy	IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)	Treatment	sonia.contrerasmartinez@ucsf.edu
23852	NCT03589339	Chan, Jason	A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy	Treatment	sonia.contrerasmartinez@ucsf.edu
ALLIANCE-A091903	NCT05111574	Tsai, Katy	A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma	Treatment	sonia.contrerasmartinez@ucsf.edu
22992	NCT05533697	Daud, Adil	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
22856	NCT05340621	Tsai, Katy	NAUTILUS: A Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients With Advanced NRAS-Mutated Melanoma (Phase 2)	Treatment	sonia.contrerasmartinez@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
238510	NCT06101134	Daud, Adil	A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma	Treatment	sonia.contrerasmartinez@ucsf.edu
Cutaneous > Squamous Cell Carcinoma					
20864	NCT04349436	Tsai, Katy	An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma	Treatment	sonia.contrerasmartinez@ucsf.edu
Cutaneous > Melanoma > Immunotherapy					
18991	NCT03486873	Daud, Adil	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	Treatment	Adil.Daud@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Pancreatic Cancer					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
21458	NCT04787991	Ko, Andrew	A Multicenter, Open-label, Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)	Treatment	jennifer.luan@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Colon Cancer					
234513	NCT05419011	Singh, Aparajita	A PHASE IIB CLINICAL TRIAL OF THE MULTITARGETED RECOMBINANT ADENOVIRUS 5 (CEA/MUC1/BRACHYURY) VACCINES (TRI-AD5) AND IL-15 SUPERAGONIST N-803 IN LYNCH SYNDROME	Prevention	rachaelleigh.delacruz@ucsf.edu
Gastrointestinal > Rectal Cancer					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma)					
234510	NCT06160752	Kelley, Robin	A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors with Activating FGFR2 Gene Alterations (SURF-201)	Treatment	quincy.harris@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Resectable					
A021806	NCT04340141	Ko, Andrew	A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Treatment	khuong.le@ucsf.edu
Gastrointestinal > Colon Cancer > Resectable					
NRG-GI008	NCT05174169	Eftimie, Bogdan	NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)	Treatment	Bogdan.Eftimie@ucsf.edu
Gastrointestinal > Rectal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Gastrointestinal Stromal Tumor (GIST) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Anal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Metastatic					
20451	NCT03825289	Ko, Andrew	THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer	Treatment	banaz.shwan@ucsf.edu
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	brittany.liu@ucsf.edu
Gastrointestinal > Colon Cancer > Resectable > Adjuvant (after surgery)					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Metastatic > First-Line					
23453	NCT05669482	Ko, Andrew	A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas	Treatment	insiyah.merchant@ucsf.edu; kevin.lopez@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Anal Cancer > Localized > HIV Positive					
AMC-110	NCT04929028	Wang, Chia-Ching	Risk-adapted therapy for HIV-associated anal cancer	Treatment	Paul.Couey@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Metastatic > Second-Line and Beyond					
224514	NCT05249101	Walker, Evan	A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy	Treatment	1-877-827-3222
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
22705	NCT05319314	Keenan, Bridget	A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer	Treatment	1-877-827-3222
187015	NCT03844750	Atreya, Chloe	A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases	Treatment	ashley.bolden@ucsf.edu
237010	NCT05674526	Keenan, Bridget	A Phase 1/b Study of WU-NK-101 in Combination with Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Treatment	1-877-827-3222
Gastrointestinal > Pancreatic Cancer > Metastatic > Second-Line and Beyond					
ALLIANCE-A022106	NCT06115499	Ko, Andrew	Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)	Treatment	Dalila.Stanfield@ucsf.edu
238011	NCT06077487	Anderson, Brian	Pilot Study of Ketamine-assisted Talk Therapy for Demoralization in Patients With Pancreatic Ductal Adenocarcinoma and Pain	Supportive Care	1-877-827-3222
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > Second-Line and Beyond					
237012	NCT06084884	Keenan, Bridget	A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent HEpatocellular CarciNomA: ATHENA	Treatment	1-877-827-3222
Gastrointestinal > Neuroendocrine Tumors (NET) > Well-Differentiated Neuroendocrine Tumor > Pancreatic NET > Metastatic / Unresectable > Liver-Directed					
22457	NCT05477576	Bergsland, Emily	Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)	Treatment	faiz.ibrahim@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Bladder Cancer					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
Genitourinary > Prostate Cancer					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
NRG-GU010	NCT05050084	Seyedin, Steven	NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)	Treatment	jamese.johnson@ucsf.edu
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
NRG-GU008	NCT04134260	Seyedin, Steven	RANDOMIZED PHASE III TRIAL INCORPORATING APALUTAMIDE AND ADVANCED IMAGING INTO SALVAGE TREATMENT FOR PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY	Treatment	1-877-827-3222
Genitourinary > Renal Cell Carcinoma					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
18525	NCT04258462	Wang, Jane Zhen	Hyperpolarized 13C pyruvate metabolic MRI to predict renal tumor aggressiveness	Diagnostic	khadija.siddiqua@ucsf.edu
23523	NCT05678673	Desai, Arpita	A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	Treatment	GUtrials@ucsf.edu
Genitourinary > Testicular Cancer					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	Hyunju.Lee@ucsf.edu
Genitourinary > Renal Cell Carcinoma > Adjuvant					
24521	NCT06307431	Fitzgerald, Kelly	A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma	Treatment	GUtrials@ucsf.edu
24706	NCT04696731	Oh, David	A PHASE 1A/1B MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF ALLO-316 WITH CYCLOPHOSPHOMIDE/FLUDARABINE LYMPHODEPLETION ALONE OR INCLUDING ALLO-647 IN SUBJECTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (ccRCC)	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Bladder Cancer > Metastatic					
24523	NCT06225596	Friedlander, Terence	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Treatment	GUtrials@ucsf.edu; lisa.kody@ucsf.edu
24526	NCT06506955	Koshkin, Vadim	An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study	Other	GUtrials@ucsf.edu
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC)					
24558	NCT06318273	Aggarwal, Rahul	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer	Treatment	GUtrials@ucsf.edu
209210	NCT05245006	Flavell, Robert	A First-in-Human, Pilot PET imaging Study of 89Zr-DFO-YS5, an immunoPET agent for detecting CD46 positive malignancy in men with Prostate Cancer	Diagnostic	maya.aslam@ucsf.edu
23553	NCT06171139	Kwon, Daniel	Developing and testing a patient-centered tumor genomic pre-test counseling tool for Black or African-American men with metastatic prostate cancer	Health Services Research	1-877-827-3222
23921	NCT05888532	Aggarwal, Rahul	A First-in-Human, Phase I/II PET imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients with Advanced Malignancies	Diagnostic	khadija.siddiqua@ucsf.edu; maya.aslam@ucsf.edu
Genitourinary > Prostate Cancer > Localized > Pre-Therapy / Neoadjuvant					
18702	NCT03821246	Oh, David	An open-label multi-center phase II study of neoadjuvant atezolizumab-based combination therapy in men with localized prostate cancer prior to radical prostatectomy	Treatment	Julie.McCluggage@ucsf.edu
23922	NCT05851365	Flavell, Robert	A pilot study of magnetic resonance (MR) imaging with hyperpolarized bicarbonate (13C) to measure tissue pH in localized prostate cancer	Diagnostic	maya.aslam@ucsf.edu
15557	NCT02526368	De Kouchkovsky, Ivan	A Pilot Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer	Diagnostic	francesca.delasalas@ucsf.edu
Genitourinary > Prostate Cancer > Localized > Adjuvant					
175516	NCT03933670	De Kouchkovsky, Ivan	A Phase 2 Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) in Patients with Prostate Cancer on Active Surveillance	Diagnostic	khadija.siddiqua@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
21556	NCT04986423	Aggarwal, Rahul	A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer	Treatment	1-877-827-3222
23551	NCT05766371	Aggarwal, Rahul	A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients with Metastatic Castration Resistant Prostate Cancer	Treatment	GUTrials@ucsf.edu
21555	NCT05011188	Aggarwal, Rahul	A Phase 1b/2 Study of FOR46 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer	Treatment	GUTrials@ucsf.edu
Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy					
22524	NCT04879329	Koshkin, Vadim	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Resistant					
219516	NCT04662580	Aggarwal, Rahul	A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 in Subjects with Metastatic Castration-Resistant Prostate Cancer who are Resistant or Refractory to Prior Standard Therapies	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
224010	NCT04606914	Chapman, Jocelyn	Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor alpha positive	Treatment	Nathalie.Halley2@ucsf.edu
224011	NCT05523700	Chen, Lee-may	Value-Based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)	Supportive Care	1-877-827-3222
NRG-GY027	NCT05276973	Fuh, Katherine	PHASE I/IB SAFETY AND PHARMACODYNAMIC STUDY OF NEOADJUVANT (NACT) PACLITAXEL AND CARBOPLATIN WITH IPATASERTIB AS INITIAL THERAPY OF OVARIAN CANCER PTMA 100805	Treatment	Nathalie.Halley2@ucsf.edu
Gynecological > Corpus/Endometrial					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	emontenegro@chla.usc.edu; erin.vanblarigan@ucsf.edu
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	Hyunju.Lee@ucsf.edu
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > BRCA					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx)					
NRG-HN009	NCT05050162	Chan, Jason	NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)	Treatment	jamese.johnson@ucsf.edu
NRG-HN006	NCT04333537	Chan, Jason	RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER	Treatment	jamese.johnson@ucsf.edu
22721	NCT05273307	Yom, Sue	Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial	Supportive Care	jamese.johnson@ucsf.edu
23203	NCT06097468	Yom, Sue	A Phase I/IIa, Single-Arm, Dose-Confirmation and Dose-Expansion Study Evaluating Changes in the Oral Microbiome of Patients with Oral Cavity Squamous Cell Carcinoma (OSCC) after Short-Term Ingestion of Nisin, a Naturally Occurring Food Preservative	Treatment	angelica.valadez@ucsf.edu
Head and Neck > Adenoid Cystic / Salivary					
22721	NCT05273307	Yom, Sue	Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial	Supportive Care	jamese.johnson@ucsf.edu
NRG-HN010	NCT05408845	Kang, Hyunseok	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer	Treatment	angelica.valadez@ucsf.edu
21728	NCT04883671	Yom, Sue	Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR trial	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional					
22203	NCT04892173	Yom, Sue	A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Metastatic					
24951	NCT06118086	Kang, Hyunseok	A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy					
23209	NCT06056310	Yom, Sue	A Single Arm, Open label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy	Treatment	angelica.valadez@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Metastatic > All others					
23201	NCT05653882	Algazi, Alain	An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors	Treatment	angelica.valadez@ucsf.edu
237010	NCT05674526	Keenan, Bridget	A Phase 1/b Study of WU-NK-101 in Combination with Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy > Peri Operative					
177018	NCT03708224	Algazi, Alain	A Phase II Study of Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck	Treatment	kira.chan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Acute Myeloid Leukemia (AML)					
23259	NCT05918692	Smith, Catherine	A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia	Treatment	jungeun.kim@ucsf.edu
172521	NCT03013998	Olin, Rebecca	A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	Treatment	Jenai.Wilmoth@ucsf.edu
22257	NCT05682170	Smith, Catherine	A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > T-Cell Lymphoma					
212531	NCT05351593	Rubenstein, James	A Phase I/II Study of Tafasitamab plus Lenalidomide in Relapsed CNS Lymphoma	Treatment	1-877-827-3222
SWOG-S2114	NCT05633615	Seshadri, Madhav	A Randomized Phase II trial of consolidation therapy following CD19 CAR T-Cell treatment for Relapsed/Refractory large B-cell lymphoma or Grade IIIB follicular lymphoma	Treatment	Samantha.Zylberman@ucsf.edu
Malignant Hematology > Acute Lymphoblastic Leukemia (ALL)					
23252	NCT05041309	Logan, Aaron	Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells	Other	lena.truong3@ucsf.edu; mahum.kudia@ucsf.edu
Malignant Hematology > Chronic Myeloid Leukemia (CML)					
21257	NCT04372433	Dunavin, Neil	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients	Treatment	Jenai.Wilmoth@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Non-Hodgkin Lymphoma (NHL)					
16252	NCT02445222	Andreadis, Charalambos	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	Other	Jenai.Wilmoth@ucsf.edu
237011	NCT06028373	Keenan, Bridget	A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas	Treatment	1-877-827-3222
ALLIANCE-A051901	NCT04609046	Rubenstein, James	Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma	Treatment	Jenai.Wilmoth@ucsf.edu
22706	NCT05169515	Andreadis, Charalambos	A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA	Treatment	1-877-827-3222
20924	NCT04656431	Rubenstein, James	Pilot Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma	Diagnostic	James.Rubenstein@ucsf.edu; Wendy.Ma@ucsf.edu
ECOG-ACRIN-EA4151	NCT03267433	Spinner, Michael	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission	Treatment	hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM)					
23925	NCT05892393	Flavell, Robert	Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma	Diagnostic	maya.aslam@ucsf.edu
24253	NCT05257083	Chung, Alfred	A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucl versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible	Treatment	Samantha.Zylberman@ucsf.edu
Malignant Hematology > Amyloidosis > Untreated					
202515	NCT04504825	Chung, Alfred	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative					
202523	NCT04663347	Andreadis, Charalambos	A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody@-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)	Treatment	Jenai.Wilmoth@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > T-Cell Lymphoma > Relapsed/Refractory					
23258	NCT05131022	Rubenstein, James	A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degradator, in Adults with Relapsed/Refractory B-cell Malignancies	Treatment	1-877-827-3222
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
212536	NCT05201781	Martin, Tom	Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel	Other	hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu
Malignant Hematology > T-Cell Lymphoma > Relapsed/Refractory					
212523	NCT05011058	Ai, Weiyun	An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Amyloidosis > Relapsed/Refractory					
22253	NCT05486481	Chung, Alfred	A Multicenter Phase 1/2 study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis Patients with Translocation (11;14) (ALTITUDE STUDY)	Treatment	1-877-827-3222
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
24704	NCT05652335	Chari, Ajai	Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis	Treatment	ashley.bolden@ucsf.edu
Malignant Hematology > Amyloidosis > Relapsed/Refractory					
24704	NCT05652335	Chari, Ajai	Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis	Treatment	ashley.bolden@ucsf.edu
Malignant Hematology > Hodgkin Disease > Relapsed / Refractory					
24254	NCT06120504	Spinner, Michael	A phase 1, open-label study to evaluate SGN-35C in adults with advanced malignancies.	Treatment	essence.fisherhobson@ucsf.edu
212523	NCT05011058	Ai, Weiyun	An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
212533	NCT05050097	Martin, Tom	A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma	Treatment	1-877-827-3222
Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory					
212524	NCT04811560	Dunavin, Neil	A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia	Treatment	Jenai.Wilmoth@ucsf.edu; hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Acute Lymphoblastic Leukemia (ALL) > Relapsed / Refractory					
APAL2020SC	NCT04726241	Stieglitz, Elliot	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias	Screening	shani.lyubomirsky@ucsf.edu
212524	NCT04811560	Dunavin, Neil	A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia	Treatment	Jenai.Wilmoth@ucsf.edu; hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu
Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory					
21257	NCT04372433	Dunavin, Neil	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients	Treatment	Jenai.Wilmoth@ucsf.edu
207019	NCT03190278	Olin, Rebecca	Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia	Treatment	Julie.McCluggage@ucsf.edu
APAL2020SC	NCT04726241	Stieglitz, Elliot	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias	Screening	shani.lyubomirsky@ucsf.edu
Malignant Hematology > Acute Lymphoblastic Leukemia (ALL) > Relapsed / Refractory > Under 60 years of age					
23252	NCT05041309	Logan, Aaron	Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells	Other	lena.truong3@ucsf.edu; mahum.kudia@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
23951	NCT05651932	Chung, Alfred	A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma	Treatment	savannah.berkley@ucsf.edu
24251	NCT06297226	Kumar, Anupama	A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma	Treatment	Jenai.Wilmoth@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory > Aggressive					
232516	NCT06252675	Andreadis, Charalambos	A Multicenter Phase 2 Study of Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Multiple / III-Defined Disease Sites > Solid Tumors					
22954	NCT05032040	Aggarwal, Rahul	A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer	Treatment	bryan.chu2@ucsf.edu
22956	NCT05462717	Munster, Pamela	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	Treatment	zach.schoenherr@ucsf.edu
21708	NCT04626635	Keenan, Bridget	A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Treatment	1-877-827-3222
22801	NCT05297734	Dixit, Niharika	Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer	Supportive Care	1-877-827-3222
237011	NCT06028373	Keenan, Bridget	A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas	Treatment	1-877-827-3222
229510	NCT05694715	Munster, Pamela	Combination Therapy of Niraparib and Irinotecan in Cancers with Mutations in DNA Repair Genes	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; kelsey.cordero@ucsf.edu
21705	NCT04799054	Algazi, Alain	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies	Treatment	1-877-827-3222
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
189510	NCT03682289	Aggarwal, Rahul	Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies	Treatment	1-877-827-3222
22951	NCT05094336	Munster, Pamela	A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors	Treatment	1-877-827-3222
20929	NCT04621435	Hope, Thomas	Imaging of Solid Tumors Using FAP-2286	Diagnostic	brad.kline@ucsf.edu; maya.aslam@ucsf.edu
23953	NCT05768139	Munster, Pamela	First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	Treatment	cindy.zhang@ucsf.edu
22953	NCT05277051	Munster, Pamela	A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors	Treatment	Sukjun.Lee@ucsf.edu; bryan.chu2@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Neurologic Oncology > Adult Glioma (Age >= 18)					
13106	NCT03739411	Chang, Susan	Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients with Gliomas	Diagnostic	Jane.Rabbitt@ucsf.edu
23102	NCT05503797	Butowski, Nicholas	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations	Treatment	1-877-827-3222
Neurologic Oncology > Adult Brain Tumors, Other (Non-Glioma)					
NRG-BN012	NCT05438212	Braunstein, Steve	NRG-BN012: A RANDOMIZED PHASE III TRIAL OF PRE-OPERATIVE COMPARED TO POST-OPERATIVE STEREOTACTIC RADIOSURGERY IN PATIENTS WITH RESECTABLE BRAIN METASTASES	Treatment	jamese.johnson@ucsf.edu
Neurologic Oncology > Adult Brain Tumors, Other (Non-Glioma) > Meningioma					
23924	NCT06014905	Villanueva-Meyer, Javier	Pilot/Phase I study of feasibility of acquiring hyperpolarized imaging in patients with meningioma	Diagnostic	Alya.Briceno@ucsf.edu; Wendy.Ma@ucsf.edu
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma)					
221022	NCT05484622	Clarke, Jennifer	A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Glioma	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Newly diagnosed > Nonsurgical					
231010	NCT05708352	Butowski, Nicholas	A randomized controlled phase 2 study of the ketogenic diet versus standard dietary guidance for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Thoracic > Non-small cell Lung Cancer					
ECOG-ACRIN-EA5163	NCT03793179	Wang, Chia-Ching	EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis	Treatment	Paul.Couey@ucsf.edu
Thoracic > Small cell Lung Cancer					
22658	NCT05595460	Mulvey, Claire	Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)	Treatment	lisa.tan@ucsf.edu
Thoracic > Sarcoma					
216511	NCT04950075	Wang, Victoria	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Treatment	1-877-827-3222
Thoracic > Non-small cell Lung Cancer > By Stage					
SWOG-S2302	NCT05633602	Wang, Sunny	S2302, PRAGMATICA- Lung: A Prospective Randomized Study of Ramucirumab (LY3009806, NSC749128) Plus Pembrolizumab (MK-3475; NSC:776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer	Treatment	Bogdan.Eftimie@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology					
24651	NCT06162221	Cheng, Michael	A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)	Treatment	lisa.tan@ucsf.edu
22659	NCT04302025	Blakely, Collin	NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Treatment	jamese.johnson@ucsf.edu; lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > KRAS Mutation					
23653	NCT05609578	Blakely, Collin	A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation	Treatment	lisa.tan@ucsf.edu
22657	NCT05375994	Blakely, Collin	A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)	Treatment	lisa.tan@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation > 2nd Line and Above					
19655	NCT04085315	Blakely, Collin	A phase I/Ib study of Alisertib in combination with Osimertinib in metastatic EGFR-mutant lung cancer	Treatment	lisa.tan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
her Trials					
24083	NCT02559778	Michlitsch, Jennifer	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDI-PLAN): A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu; teran.nieman@ucsf.edu
EA-JCAR017-001-ANDREADIS	NCT04400591	Andreadis, Charalambos	EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE	Other	1-877-827-3222
ECOG-ACRIN-EA8184	NCT04597359	Ekstrand, Bradley	A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers	Prevention	1-877-827-3222
ALLIANCE-A081801	NCT04267848	Wang, Sunny	ALLIANCE A081801: INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)	Treatment	1-877-827-3222
23706	NCT04844073	Keenan, Bridget	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer	Treatment	1-877-827-3222
ALLIANCE-A222004	NCT04939090	Dixit, Niharika	A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA	Supportive Care	Paul.Couey@ucsf.edu
24953	NCT05838768	Munster, Pamela	An open-label, multi-center phase I/Ib dose finding and expansion study of HRO761 as single agent and in combinations in patients with Microsatellite Instability-High or Mismatch Repair Deficient advanced solid tumors	Treatment	1-877-827-3222
160814	NCT02617407	Den Besten, Pamela	Pilot Study: Oral Microbiome and Dental Plaque Control with Livionex Dental Gel in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)	Prevention	janelle.urata@ucsf.edu
18863	NCT03767348	Tsai, Katy	An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
SWOG-LUNGMAP-S1900E	NCT04625647	Wang, Sunny	A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP sub-study)	Treatment	1-877-827-3222
21403	NCT04486352	Alvarez, Edwin	EndoMAP: A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer	Treatment	Chetna.Nangia@ucsf.edu; Nathalie.Halley2@ucsf.edu
21259	NCT04771078	Martin, Tom	Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucl That is Nonconforming for Commercial Release	Other	Jenai.Wilmoth@ucsf.edu; hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
228012	NCT05807074	Piper, Merisa	The Impact of Tranexamic Acid in Reducing Hematoma and Seroma Formation in Reconstructive Post-Oncologic Breast Surgery	Supportive Care	1-877-827-3222
230827	NCT05533775	Michlitsch, Jennifer	A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	Treatment	teran.nieman@ucsf.edu
227011	NCT04986865	Keenan, Bridget	A First-in-Human Phase I Trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Treatment	Elaine.Esler@ucsf.edu
23704	NCT06186401	Clarke, Jennifer	Phase 1 Study of Autologous anti-EGFRvIII synNotch Receptor Induced anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells in Adult Participants with EGFRvIII+ Glioblastoma	Treatment	abigail.hansen@ucsf.edu
23552	NCT05946603	Nguyen, Hao	Phase 2 Multi-Center Randomized Controlled Feasibility Study of IS-002 in Subjects Undergoing Robotic-Assisted Radical Prostatectomy Using the da Vinci® Surgical System With Firefly® Fluorescence Imaging	Other	1-877-827-3222
23107	NCT05275478	Butowski, Nicholas	A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-Tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
ALLIANCE-A022104	NCT05610163	Eftimie, Bogdan	The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer	Treatment	Bogdan.Eftimie@ucsf.edu
24402	NCT06072781	Chapman, Jocelyn	A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	Treatment	Nathalie.Halley2@ucsf.edu
RTOG-1216	NCT01810913	Chan, Jason	Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck	Treatment	jamese.johnson@ucsf.edu
202014	NCT04588038	Kang, Hyunseok	A Window of Opportunity Trial of NT-17 in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery	Treatment	angelica.valadez@ucsf.edu
21631	NCT04855357	Vijayaraghavan, Maya	A community-based trial of a voluntary smoke-free home intervention in permanent supportive housing for formerly homeless adults	Prevention	1-877-827-3222
21727	NCT05021185	Tsoh, Janice	Interactive Mobile Doctor (iMD) to Promote Tobacco Cessation among Cancer Patients	Prevention	1-877-827-3222
NRG-GI005	NCT04068103	Malhotra, Akshiv	Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
SWOG-S1827	NCT04155034	Wang, Sunny	MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer	Treatment	1-877-827-3222
22703	NCT05239143	Oh, David	A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS	Treatment	1-877-827-3222
21636	NCT04627922	Herbst, Ellen	N-Acetylcysteine for Smoking Cessation in Cigarette-Cannabis Co-Users: A Randomized Controlled Trial	Prevention	1-877-827-3222
ALLIANCE-A211801	NCT04711109	Munster, Pamela	BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation	Prevention	1-877-827-3222
221018	NCT05383872	de Groot, John	A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma Brain Tumors	Diagnostic	1-877-827-3222
240816	NCT05489887	Michlitsch, Jennifer	A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu; teran.nieman@ucsf.edu
229511	NCT05315700	Cheng, Michael	An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Treatment	lisa.tan@ucsf.edu
23952	NCT05107674	Munster, Pamela	A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types	Treatment	1-877-827-3222
EA-MARTIN-05092023	NCT05346835	Martin, Tom	Expanded Access: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucl (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma	Other	1-877-827-3222
23958	NCT06077877	Munster, Pamela	A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.	Treatment	1-877-827-3222
24955	NCT04855656	Aggarwal, Rahul	Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)	Treatment	1-877-827-3222
16751	NCT03011684	Rosen, Mitchell	Fertility Preservation Using Tamoxifen or Letrozole in Estrogen Sensitive Tumors Trial (TALES Trial)	Supportive Care	Flor.Juarez-Hernandez@ucsf.edu
19653	NCT04123535	Bucknor, Matthew	Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma	Treatment	louise.magat@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
19089	NCT03509961	Higham, Christine	A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative	Treatment	magruderk@radonc.ucsf.edu
24088	NCT04301843	Michlitsch, Jennifer	Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu
197021	NCT04221542	Aggarwal, Rahul	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer	Treatment	Julie.McCluggage@ucsf.edu
20527	NCT04626479	Desai, Arpita	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03A	Treatment	1-877-827-3222
21457	NCT05028725	Buckle, Geoffrey	Investigation of a Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma	Diagnostic	1-877-827-3222
ALLIANCE-A021901	NCT04665739	Mulvey, Claire	Randomized Phase II Trial of Lutetium Lu177 DOTATATE Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors	Treatment	1-877-827-3222
230826	NCT04696029	Hastings, Caroline	Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma	Treatment	1-877-827-3222
210813	NCT05478837	Mueller, Sabine	A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M with Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants with H3.3K27M-positive Diffuse Midline Gliomas	Treatment	karina.wong@ucsf.edu
22054		Gomez, Scarlett	The Patient Care Outreach, Navigation, Technology and Support 2.0 Study	Health Services Research	1-877-827-3222
23702	NCT04471727	Aggarwal, Rahul	A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)	Treatment	1-877-827-3222
24921	NCT06074510	Carroll, Peter	A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer	Diagnostic	1-877-827-3222
24957	NCT06232408	Aggarwal, Rahul	Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors	Treatment	1-877-827-3222
161016	NCT04540107	Chang, Susan	Metabolic Imaging of Patients with Lower Grade Glioma using Hyperpolarized 13C Pyruvate	Diagnostic	Wendy.Ma@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
177017	NCT03435796	Andreadis, Charalambos	LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH CAR T CELLS	Other	Julie.McCluggage@ucsf.edu
ALLIANCE--A151216	NCT02194738	Wang, Sunny	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	Screening	1-877-827-3222
197017	NCT04370509	Oh, David	A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy	Treatment	1-877-827-3222
21751	NCT05456373	Wong, Jasmine	Intraoperative Use of ClearEdge Device in Breast Conserving Surgery	Treatment	1-877-827-3222
21208	NCT05152927	Duh, Quan-Yang	Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands during Parathyroidectomy	Prevention	1-877-827-3222
215510	NCT05113537	Koshkin, Vadim	Phase I/II Study of CDK4/6 Inhibition with Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy	Treatment	GUtrials@ucsf.edu
22925	NCT05851378	Chang, Susan	Hyperpolarized carbon-13 alpha-ketoglutarate metabolic imaging in IDH mutant glioma	Diagnostic	1-877-827-3222
22709	NCT05519449	Oh, David	A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	Treatment	Kiev.Gimpel-tetra@ucsf.edu; andrea.skafel@ucsf.edu
23104	NCT04528680	Butowski, Nicholas	Phase I/II trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device and treatment with albumin-bound paclitaxel and carboplatin in patients with recurrent glioblastoma	Treatment	1-877-827-3222
SWOG-LUNGMAP-S1900G	NCT05642572	Wang, Sunny	Lung-MAP: S1900G, A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	Treatment	1-877-827-3222
CTSU-EA1151	NCT03233191	Freimanis, Rita	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	Screening	1-877-827-3222
SWOG-LUNGMAP	NCT03851445	Eftimie, Bogdan	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	Screening	1-877-827-3222
19703	NCT04545762	Andreadis, Charalambos	A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Treatment	Julie.McCluggage@ucsf.edu
195511	NCT04335682	Kwon, Daniel	ARACOG: A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide	Other	1-877-827-3222
19109	NCT04659811	Oberheim Bush, Nancy Ann	A Phase II Study of Stereotactic Radiosurgery in Conjunction with the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma	Treatment	karishma.kumar@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
240811	NCT02875314	Hastings, Caroline	HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with either Single Cell (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue	Treatment	1-877-827-3222
ALLIANCE-A221805	NCT04137107	Friedlander, Terence	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	Supportive Care	ivan.leung@ucsf.edu
21955	NCT04143711	Munster, Pamela	A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Treatment	bryan.chu2@ucsf.edu
226310	NCT05829824	Tsoh, Janice	Connect Cancer Patients to Tobacco Cessation Care by Automated Interactive Outreach	Prevention	1-877-827-3222
23052		Yu, Diana	Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier - with Familiarization	Diagnostic	Alma.Andrade@ucsf.edu
228013	NCT05520866	Finlayson, Emily	PREHABPAL: A Digital Tool to Help Frail Elders Prepare for Cancer Surgery	Supportive Care	1-877-827-3222
23103	NCT05580562	Butowski, Nicholas	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	Treatment	1-877-827-3222
23721	NCT05665738	Hsu, I-Chow	Two-fraction High Dose Rate Brachytherapy as Monotherapy Delivered Three Hours Apart in Localized Prostate Cancer: A Pilot Study	Treatment	david.haase2@ucsf.edu
23955	NCT06264921	Alvarez, Edwin	A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF THE NOVEL ORALLY AVAILABLE CDK2 INHIBITOR NKT3447 IN ADULTS WITH ADVANCED/METASTATIC SOLID TUMORS	Treatment	kristy.tjokro@ucsf.edu
23957	NCT06014658	Munster, Pamela	A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS	Treatment	Sukjun.Lee@ucsf.edu
24952	NCT06253130	Munster, Pamela	A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and in combination in participants with advanced solid tumors	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
24702	NCT06153251	Chung, Alfred	A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma	Treatment	1-877-827-3222
20922	NCT04346225	De Kouchkovsky, Ivan	Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer	Diagnostic	kiersten.cheung@ucsf.edu
194522	NCT04430452	Feng, Mary	Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy	Treatment	jamese.johnson@ucsf.edu
EA-MAP-12519-ANDREADIS	NCT03601442	Andreadis, Charalambos	Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release (expanded access)	Other	hayleymarget.wallace@ucsf.edu; jungeun.kim@ucsf.edu
24089	NCT02679144	Michlitsch, Jennifer	NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)	Prevention	teran.nieman@ucsf.edu
20926	NCT04927663	Aggarwal, Rahul	A First-in-Human, Phase I PET imaging study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients with Advanced Solid Tumor Malignancies	Diagnostic	khadija.siddiqua@ucsf.edu
22637	NCT03950427	Leutwyler, Heather	VIP Smoking Cessation Intervention for Adults with Serious Mental Illness	Prevention	Erin.Hubbard@ucsf.edu
NRG-GU009	NCT04513717	Ekstrand, Bradley	PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation	Treatment	1-877-827-3222
221014	NCT05557292	Butowski, Nicholas	A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma	Treatment	1-877-827-3222
221013	NCT05417594	Butowski, Nicholas	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)	Treatment	1-877-827-3222
224523	NCT05746195	Van Blarigan, Erin	Optimization of Adaptive Text Messages for Cancer Survivors II (OATS II)	Supportive Care	paige.steiding@ucsf.edu
234517	NCT06084234	Mehta, Neil	National Liver Cancer Screening Trial (TRACER)	Screening	1-877-827-3222
24085	NCT04400071	Michlitsch, Jennifer	Biologic Mechanisms and Dosing of Active Music Engagement in Children with Acute Lymphoblastic Leukemia and Parents	Supportive Care	nicole.elzie-tuttle@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
20551	NCT04471974	Aggarwal, Rahul	A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer	Treatment	1-877-827-3222
ECOG-ACRIN-EA5182	NCT04181060	Eftimie, Bogdan	Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)	Treatment	1-877-827-3222
21622	NCT05074264	Palefsky, Joel	Optimization of screening algorithms for cervical and anal high-grade squamous intraepithelial lesions in people living with HIV in Mexico and Puerto Rico	Screening	1-877-827-3222
221017	NCT05303467	Butowski, Nicholas	A Feasibility Study to Evaluate the Safety of the TheraSphere™ Glioblastoma (GBM) Device in Patients with Recurrent GBM	Treatment	1-877-827-3222
SWOG-S1918	NCT04799275	Ekstrand, Bradley	A PHASE II/III RANDOMIZED STUDY OF R-MINICHOP WITH OR WITHOUT CC-486 (ORAL AZACITIDINE) IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA, GRADE IIIB FOLLICULAR LYMPHOMA, TRANSFORMED LYMPHOMA, AND HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS	Treatment	1-877-827-3222
22639	NCT05351606	Bialous, Stella	Integrating Tobacco Use Cessation into HIV Care and Treatment in Ministry of Health Clinics in Kisumu County, Kenya	Prevention	1-877-827-3222
22958	NCT05746208	Bergsland, Emily	A Phase II study of lenvatinib plus pembrolizumab in well differentiated G3 neuroendocrine tumors	Treatment	Sukjun.Lee@ucsf.edu
22957	NCT05252416	Munster, Pamela	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	Treatment	1-877-827-3222
23101	NCT05753007	Butowski, Nicholas	A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients	Supportive Care	JesusEduardo.RodriguezAlmaraz@ucsf.edu
23456	NCT05968326	Ko, Andrew	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA	Treatment	1-877-827-3222
232513	NCT06160791	Lee, Jerry	Frontline Ruxolitinib with De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study	Treatment	1-877-827-3222
24631	NCT06170437	Vijayaraghavan, Maya	Healthy Homes Study: A protocol for a place-based smoke-free home intervention in federally subsidized housing	Health Services Research	Maya.Vijayaraghavan@ucsf.edu
23657	NCT06012435	Cheng, Michael	A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer	Treatment	lisa.tan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
249511	NCT06084481	Munster, Pamela	A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications	Treatment	Kaiulani.Williams@ucsf.edu
237013	NCT05220098	Keenan, Bridget	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Treatment	1-877-827-3222